Key Points
- Christian Michael Glibert, a major shareholder, bought 240,000 shares of Nanovibronix on Jan. 14 at $2.67 each for $640,800, bringing his direct ownership to 240,000 shares; the transaction was disclosed in an SEC filing.
- Nanovibronix (NASDAQ:FEED) opened at $2.71 and has a one‑year range of $0.99–$162.50, while Weiss Ratings initiated coverage with a "sell (e+)" and the stock's average analyst rating is currently "Sell".
Nanovibronix, Inc. (NASDAQ:FEED - Get Free Report) major shareholder Christian Michael Glibert purchased 240,000 shares of the business's stock in a transaction on Wednesday, January 14th. The shares were bought at an average price of $2.67 per share, for a total transaction of $640,800.00. Following the purchase, the insider directly owned 240,000 shares in the company, valued at $640,800. This represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.
Nanovibronix Stock Performance
NASDAQ FEED opened at $2.71 on Thursday. Nanovibronix, Inc. has a 1 year low of $0.99 and a 1 year high of $162.50.
Analyst Ratings Changes
Separately, Weiss Ratings started coverage on Nanovibronix in a research note on Tuesday, January 27th. They set a "sell (e+)" rating for the company. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of "Sell".
Read Our Latest Stock Analysis on Nanovibronix
About Nanovibronix
(
Get Free Report)
Nanovibronix (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non‑invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company's product portfolio centers on wearable ultrasound devices designed to deliver low‑intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound‑care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings.
The company concentrates its commercial efforts on supplying hospitals, wound‑care clinics, long‑term care facilities and patients requiring home‑based therapies.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
